Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2021 | Original Article

Synthesis, preclinical evaluation, and a pilot clinical imaging study of [¹⁸F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [⁶⁸Ga]Ga-DOTA-TATE

Authors: Qing Xie, Teli Liu, Jing Ding, Nina Zhou, Xiangxi Meng, Hua Zhu, Nan Li, Jiangyuan Yu, Zhi Yang

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2021

Abstract

Purpose

A [¹⁸F]AlF-labeled somatostatin receptor (SSTR) antagonist was developed for imaging of neuroendocrine neoplasms (NENs), evaluated and compared with [⁶⁸Ga]Ga-DOTA-TATE.

Method

[¹⁸F]AlF-NOTA-JR11 was synthesized manually and qualified with high-performance liquid chromatography (HPLC) and liquid chromatography–mass spectrometry (LC-MS). The cellular uptake, internalization, and saturation binding were performed with HEK293-SSTR2 cells. Biodistribution and micro-PET imaging were carried out with HEK293-SSTR2 tumor-bearing mice. [¹⁸F]AlF-NOTA-JR11 PET/MR imaging and [⁶⁸Ga]Ga-DOTA-TATE PET/CT were performed with ten patients of NEN at 50~60 min post-injection (p.i.). Normal organ biodistribution and tumor detectability were evaluated.

Result

[¹⁸F]AlF-NOTA-JR11(24~36 GBq/μmol) was prepared within 30 min and 51.35 ± 3.30% (n > 10)of radiochemical yield. The radiochemical purity was 98.74 ± 1.24% (n > 10). Two stereoisomers were found and confirmed by LC-MS. The cellular uptake of [¹⁸F]AlF-NOTA-JR11 and [⁶⁸Ga]Ga-DOTA-TATE were 4.50 ± 0.31 and 4.50 ± 0.13 %AD/10⁵ cells at 30 min, and the internalization at 37 °C of [¹⁸F]AlF-NOTA-JR11 (5.47 ± 0.32% at 60 min) was significantly lower than [⁶⁸Ga]Ga-DOTA-TATE (66.89 ± 1.62% at 60 min). The affinity of [¹⁸F]AlF-NOTA-JR11 (K_d = 11.59 ± 1.31 nM) was slightly lower than [⁶⁸Ga]Ga-DOTA-TATE (K_d = 7.36 ± 1.02 nM); [¹⁸F]AlF-NOTA-JR11 showed high uptake in tumor (9.02 ± 0.92 %ID/g at 60 min p.i.) which can be blocked by 50 μg of NOTA-JR11 (3.40 ± 1.64 %ID/g at 60 min p.i.); the result was coincident with micro-PET imaging. Imaging study of NEN patients showed that more lesions were found only by [¹⁸F]AlF-NOTA-JR11 (n = 67 vs. 1 only by [⁶⁸Ga]Ga-DOTA-TATE), and the uptakes of [¹⁸F]AlF-NOTA-JR11 in majority normal organs were significantly lower than [⁶⁸Ga]Ga-DOTA-TATE. The target to nontarget of maximum of standard uptake value (SUVmax) of [¹⁸F]AlF-NOTA-JR11 in liver lesions were significantly higher than those of [⁶⁸Ga]Ga-DOTA-TATE.

Conclusion

Qualitied [¹⁸F]AlF-NOTA-JR11 is prepared conveniently with reasonable yield, and it can bind SSTR2 specifically with high affinity. Excellent imaging capability of [¹⁸F]AlF-NOTA-JR11 for NENs is superior to [⁶⁸Ga]Ga-DOTA-TATE, especially in digestive system. It has a great potential for imaging of NENs.

Available only for authorised users

Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl. 1):3–7.CrossRef

Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–88. https://doi.org/10.1111/j.1365-2036.2009.04174.x.CrossRefPubMed

Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76. https://doi.org/10.1159/000335597.CrossRefPubMed

Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues [published correction appears in J Nucl Med. 2009 Oct;50(10):1578]. J Nucl Med. 2009;50(6):936–41. https://doi.org/10.2967/jnumed.108.061457.CrossRefPubMed

Cescato R, Schulz S, Waser B, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006;47(3):502–11.PubMed

Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000;27(9):1318–25. https://doi.org/10.1007/s002590000289.CrossRefPubMed

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18. https://doi.org/10.2967/jnumed.106.035667.CrossRefPubMed

Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55(8):1248–52. https://doi.org/10.2967/jnumed.114.138834.CrossRefPubMed

Nicolas GP, Schreiter N, Kaul F, et al. Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59(6):915–21. https://doi.org/10.2967/jnumed.117.199760.CrossRefPubMed

10.

Fani M, Del Pozzo L, Abiraj K, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52(7):1110–8. https://doi.org/10.2967/jnumed.111.087999.CrossRefPubMed

11.

Johnbeck CB, Knigge U, Loft A, et al. Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med. 2017;58(3):451–7. https://doi.org/10.2967/jnumed.116.180430.CrossRefPubMed

12.

Zhu W, Cheng Y, Wang X, et al. Head-to-head comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61(6):897–903. https://doi.org/10.2967/jnumed.119.235093.CrossRefPubMedPubMedCentral

13.

D'Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22(9):1793–803. https://doi.org/10.1021/bc200175c.CrossRefPubMedPubMedCentral

14.

McBride WJ, Sharkey RM, Goldenberg DM. Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res. 2013;3(1):36. Published 2013 May 8. https://doi.org/10.1186/2191-219X-3-36.CrossRefPubMedPubMedCentral

15.

Chen Q, Meng X, McQuade P, et al. Synthesis and preclinical evaluation of folate-NOTA-Al(18)F for PET imaging of folate-receptor-positive tumors. Mol Pharm. 2016;13(5):1520–7. https://doi.org/10.1021/acs.molpharmaceut.5b00989.CrossRefPubMedPubMedCentral

16.

Liu S, Liu H, Jiang H, Xu Y, Zhang H, Cheng Z. One-step radiosynthesis of ¹⁸F-AlF-NOTA-RGD₂ for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging. 2011;38(9):1732–41. https://doi.org/10.1007/s00259-011-1847-4.CrossRefPubMedPubMedCentral

17.

McBride WJ, Sharkey RM, Karacay H, et al. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50(6):991–8. https://doi.org/10.2967/jnumed.108.060418.CrossRefPubMed

18.

Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033–46. https://doi.org/10.1007/s00259-020-04918-4.CrossRefPubMed

19.

Niedermoser S, Chin J, Wängler C, Kostikov A, Bernard-Gauthier V, Vogler N, et al. In vivo evaluation of ¹⁸F-SiFAlin-modified TATE: a potential challenge for ⁶⁸Ga-DOTATATE, the clinical gold standard for somatostatin receptor imaging with PET. J Nucl Med. 2015;56(7):1100–5. https://doi.org/10.2967/jnumed.114.149583.CrossRefPubMed

20.

Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, et al. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2020;47(4):870–80. https://doi.org/10.1007/s00259-019-04501-6.CrossRefPubMed

21.

Paspulati RM, Gupta A. PET/MR imaging in cancers of the gastrointestinal tract. PET Clin. 2016;11(4):403–23. https://doi.org/10.1016/j.cpet.2016.05.004.CrossRefPubMed

22.

Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med. 2005;46(7):1201–9.PubMed

23.

Misri R, Saatchi K, Ng SS, Kumar U, Häfeli UO. Evaluation of (111)in labeled antibodies for SPECT imaging of mesothelin expressing tumors. Nucl Med Biol. 2011;38(6):885–96. https://doi.org/10.1016/j.nucmedbio.2011.02.013.CrossRefPubMed

24.

Schottelius M, Šimeček J, Hoffmann F, Willibald M, Schwaiger M, Wester HJ. Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE. EJNMMI Res. 2015;5:22. https://doi.org/10.1186/s13550-015-0099-x.CrossRefPubMedPubMedCentral

25.

Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601. https://doi.org/10.1007/s00259-017-3728-y.CrossRefPubMed

26.

Nicolas GP, Beykan S, Bouterfa H, et al. Safety, biodistribution, and radiation dosimetry of 68Ga-OPS202 in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study. J Nucl Med. 2018;59(6):909–14. https://doi.org/10.2967/jnumed.117.199737.CrossRefPubMed

27.

Krebs S, Pandit-Taskar N, Reidy D, et al. Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46(3):677–85. https://doi.org/10.1007/s00259-018-4193-y.CrossRefPubMed

28.

Liu T, Liu C, Xu X, Liu F, Guo X, Li N, Wang X, Yang J, Yang X, Zhu H, Yang Z. Preclinical evaluation and pilot clinical study of Al¹⁸F-PSMA-BCH for prostate cancer PET imaging. J Nucl Med. 2019;60(9):1284-1292. doi: https://doi.org/10.2967/jnumed.118.221671. [29] McBride WJ, D'Souza CA, Sharkey RM, et al. Improved ¹⁸F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem 2010;21(7):1331–1340. doi:https://doi.org/10.1021/bc100137x.

29.

McBride WJ, D’Souza CA, Sharkey RM, et al. Improved ¹⁸F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. 2010;21(7):1331–40. https://doi.org/10.1021/bc100137x.CrossRefPubMedPubMedCentral

30.

Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, et al. Automated GMP compliant production of [18F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem. 2020;5(1):4. https://doi.org/10.1186/s41181-019-0084-1.CrossRefPubMedPubMedCentral

31.

Laverman P, McBride WJ, Sharkey RM, et al. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010;51(3):454–61. https://doi.org/10.2967/jnumed.109.066902.CrossRefPubMed

32.

Reubi JC, Schär JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82. https://doi.org/10.1007/s002590050034.CrossRefPubMed

33.

Cescato R, Erchegyi J, Waser B, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem. 2008;51(13):4030–7. https://doi.org/10.1021/jm701618q.CrossRefPubMedPubMedCentral

34.

Fani M, Braun F, Waser B, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53(9):1481–9. https://doi.org/10.2967/jnumed.112.102764.CrossRefPubMed

Title: Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE
Authors: Qing Xie
Teli Liu
Jing Ding
Nina Zhou
Xiangxi Meng
Hua Zhu
Nan Li
Jiangyuan Yu
Zhi Yang
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05249-8

2024 ASCO Annual Meeting

Springer Medicine

Synthesis, preclinical evaluation, and a pilot clinical imaging study of [¹⁸F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [⁶⁸Ga]Ga-DOTA-TATE

Abstract

Purpose

Method

Result

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2021

Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease

Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma

Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study

In memoriam: Marion Hendriks-de Jong

Complicated pubovesical fistula on PET/CT and MRI